Furthermore, decreased PPARδ activity cannot be explained by reduced prostacyclin production since these effects are observed in tumor cell lines irrespective of their level of COX-2 expression and also after treatment with the non-COX-inhibitory sulindac sulfone. This evidence concerns the gene PPARD and neoplasm.